Cartilage and bone metabolism (type II collagen degradation) is increased by endurance exercise with intense joint loading. Interestingly, glucosamine-containing diet exhibits a chondroprotective action on osteoarthritis by inhibiting type II collagen degradation and improves the symptoms. Thus, in the present study, we evaluated the effect of glucosamine on cartilage metabolism in collegiate soccer players and professional rugby players with intense joint loading.
Introduction
The frequency and severity of joint loading are critical factors for the development of joint destruction, characterized by the damage of articular cartilage. In fact, excessive loading on the joint with motion and exposure causes the damage of articular cartilage 1) -4) . Thus, sports with repetitive impact and torsional loading on the joints increase the risk of articular cartilage degeneration, and results in the clinical symptoms of osteoarthritis 4) .
The disease process of osteoarthritis is related to the degradation and functional loss of articular cartilage. Importantly, the early changes in the metabolic and biochemical properties of cartilage matrix can be detected before the appearance of morphological changes of cartilage 2) . Thus, various biomarkers have been developed as indicators of cartilage and bone metabolism in subjects with joint and bone disorders 5) . In this context, it is interesting to note that sports-related mechanical loading on the joints affects the turnover rate of cartilage as well as bone in humans, and these changes can be detected by the assays with biomarkers 1)-4) .
Biomarkers for cartilage and bone metabolism
Type II collagen is one of the major components of cartilage 6) , and the fragments of type II collagen are utilized as biomarkers for cartilage metabolism. A C-terminal telopeptide (CTX-II) is cleaved during degradation of type II collagen 7) , whereas a neo-epitope (C2C) is cleaved at the C terminus of the 3/4 piece of degraded type II collagen 8) . Thus, both CTX-II and C2C are used as markers for type II collagen degradation. In contrast, a C-terminal type II procollagen peptide (CPII) is present in newly formed type II procollagen and cleaved during processing of synthesized type II procollagen; thus, CPII can be used as a marker for type II collagen synthesis 9) . In addition, deoxypyridinoline (Dpyr), a crosslink product of type I collagen and a cross-linked N-terminal telopeptide of type I collagen (NTx) are used as markers for type I collagen degradation in bone (bone resorption) 5) .
Chondroprotective action of glucosamine on endurance athletes
Nutritional supplements, including glucosamine, chondroitin and collagen, are sometimes used for joint health to treat or prevent sports-related cartilage injuries (i.e., osteoarthritis) in athletes 10)-12) .
Among these, glucosamine, a naturally occurring amino monosaccharide, has been widely used to treat osteoarthritis in humans 13 . The results indicated that the levels of CTX-II and NTx are increased in the cross-country runners and crew members compared with non-athletes and swimmers, suggesting that cartilage and bone metabolism (type II and type I collagen degradation) is increased by endurance exercise with intense joint loading, such as cross county and boat racing.
So, we evaluated the effect of glucosamine on cartilage metabolism in collegiate soccer players with intense joint loading 16) . In this study, 10 nonathletes (23.5 ± 2.5 years old) and 21 soccer players (20.3 ± 0.9 years old) were recruited. Non-athletes experienced no hard exercise in the past year. In contrast, soccer players performed the training 5 days per week, and played the official match almost every weekend, during the test period.
Figures-1A and B show the urine levels of CTX-II and NTx in non-athlete controls and soccer players. In soccer players, the levels of CTX-II and NTx were significantly increased compared with non-athlete controls, indicating that cartilage and bone metabolism (type II and type I collagen degradation) is increased in soccer players, as reported in other endurance athletes 3) . Moreover, a type II collagen synthesis marker CPII was evaluated in soccer players. Interestingly, the urine level of CPII was slightly increased in soccer players compared with non-athlete controls (Figure-1C ), suggesting that cartilage metabolism as evaluated by type II collagen synthesis may be increased in soccer players. Further, we evaluated the type II collagen degradation and synthesis balance in the cartilage of soccer players by calculating CTX-II/CPII ratio. As shown in Figure-1D , the CTX-II/CPII ratio was significantly higher in soccer players than nonathlete controls, suggesting that type II collagen degradation is relatively increased compared with type II collagen synthesis in soccer players.
Next, we examined the effect of glucosamine administration on type II collagen degradation and synthesis markers. Importantly, the urine CTX-II level was significantly decreased after the glucosamine administration for 3 months at both 1.5 g and 3 g/day ( Figure-2A) . Interestingly, however, the CTX-II level returned to almost the pre-administration level after withdrawal of glucosamine administration in 1.5 g/day-group, although the CTX-II level was still reduced in 3 g/day-group. In contrast, the urine CPII level was not essentially changed even after the glucosamine administration and withdrawal of glucosamine administration (Figure-2B) , suggesting that the level of type II collagen synthesis in soccer players is maintained during the test period.
Furthermore, we evaluated the effect of glucosamine on type II collagen degradation and synthesis balance in soccer players by calculating CTX-II/CPII ratio. Importantly, the ratio was markedly reduced by glucosamine administration 
Figure-2 Effect of glucosamine administration on urine levels of CTX-II and CPII, and CTX-II/CPII ratio in soccer players
Soccer players were orally administered with glucosamine hydrochloride (GlcN; 1.5 or 3 g/day for 3 months, as indicated by an arrow). Urine levels of CTX-II (A) and CPII (B) were measured before (0 month), after the glucosamine administration (3 months) and after the withdrawal of glucosamine administration (6 months). These levels are expressed as a ratio relative to those before glucosamine administration (0 month). Furthermore, CTX-II/CPII ratios were calculated (C), using the levels of CTX-II and CPII before (0 month), after the glucosamine administration (3 months) and after the withdrawal of glucosamine administration (6 months). Data represent the mean ± SEM of 9 subjects (1.5 g GlcN/day) and 10 subjects (3 g GlcN/day). Values are compared between before (0 month) and after the glucosamine administration (3 months) or after the withdrawal of glucosamine administration (6 months). especially at 3 g/day, and returned to the pre-administration level after withdrawal of glucosamine (Figure-2C ). These observations suggest that glucosamine exhibits a chondroprotective action in soccer players by preventing type II collagen degradation but maintaining type II collagen synthesis; however, its effect on type II collagen degradation is transient and disappears after withdrawal of administration.
Further, we evaluated the effect of glucosamine on cartilage metabolism in professional rugby players with intense joint loading 17) . In this study, 19 rugby players (29.4 ± 3.7 years old) and 19 non-athletes (29.4 ± 3.7 years old) were recruited 14) . Rugby players were administered everyday with a jelly-type diet containing 3 g glucosamine for 16 weeks.
Figures-3A and B show the urine levels of CTX-II and NTx in non-athletes and rugby players. In rugby players, the levels of CTX-II and NTx were significantly increased compared with non-athletes, indicating that cartilage and bone metabolism (type II and type I collagen degradation) is increased in rugby players, as reported in soccer players and other endurance athletes 3) 16) . Next, we evaluated a type II collagen synthesis marker CPII in rugby players; however, the urine CPII level in rugby players was almost the same as in non-athletes (Figure-3C ). Based on these findings, the CTX-II/CPII ratio was slightly higher in rugby players than non-athletes (Figure-3D) , suggesting that type II collagen degradation is relatively increased compared with type II collagen synthesis in rugby players.
Next, we examined the effect of glucosamine administration on type II collagen degradation and synthesis markers. Importantly, the urine CTX-II level was significantly decreased after the glucosamine administration (Figure-4A) . Interestingly, however, the CTX-II level returned to almost the pre-administration level after withdrawal of glucosamine administration. In contrast, the urine CPII level was not essentially changed even after the ) glucosamine administration and withdrawal of glucosamine administration (Figure-4B ). Finally, we evaluated the effect of glucosamine on type II collagen degradation and synthesis balance in rugby players by calculating CTX-II/CPII ratio. Importantly, the ratio was significantly reduced by glucosamine administration, and returned to the pre-administration level after withdrawal of glucosamine (Figure-4C ). These observations suggest that glucosamine exhibits a chondroprotective action also in rugby players by preventing type II collagen degradation but maintaining type II collagen synthesis. However, the effect is transient and disappears after withdrawal of administration.
Conclusions
Type II collagen degradation is relatively increased compared with type II collagen synthesis in endurance athletes (soccer and rugby players). Glucosamine has been shown to inhibit the production of matrix metalloproteinase (MMP) -13 from chondrocytes and synoviocytes in vitro 18) 19) and decrease the serum level of MMP-3 in sera of patients with rheumatoid arthritis 20) . Based on these findings, it is interesting to speculate that glucosamine exhibits a chondroprotective action in endurance athletes (such as soccer and rugby players) by suppressing MMP production, thereby inhibiting type II collagen degradation (as evaluated by CTX-II) but maintaining type II collagen synthesis (as evaluated by CPII). However, the effect is transient and disappears after withdrawal of administration. Thus, glucosamine should be continuously administered for expecting joint health of endurance athletes. Rugby players were administered everyday with a jelly-type diet containing 3 g glucosamine for 16 weeks. Urine levels of CTX-II (A) and CPII (B) were measured before (Pre-intake), after the glucosamine administration (Post-intake) and after the withdrawal of glucosamine administration (+ 8 weeks). Moreover, the ratios of type II collagen degradation to synthesis (CTX-II/CPII) were calculated using the levels of CTX-II and CPII before (Pre-intake), after the glucosamine administration (Post-intake) and after the withdrawal of glucosamine administration (+ 8 weeks)(C). Data represent the mean ± SD of 19 subjects. Values are compared between before (Pre-intake) and after the glucosamine administration (Post-intake). ＊ p < 0.05. 
